BORGWARNER INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BORGWARNER INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.32B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $14.09B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $14.20B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $12.64B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $11.80B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $10.17B | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | $2.56B | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $2.49B | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $2.55B | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $2.57B | Feb 13, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.32B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $14.09B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $14.20B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $12.64B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $11.80B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $10.17B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $10.17B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $10.53B | Feb 22, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.67B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.65B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $2.57B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $2.37B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $2.17B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.91B | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | $545.00M | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $524.00M | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $513.00M | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $519.00M | Feb 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $277.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $338.00M | Feb 11, 2026 |
| FY2023 | Dec 31, 2023 | $154.00M | Feb 8, 2024 |
| FY2023 | Sep 30, 2023 | $50.00M | Feb 8, 2024 |
| FY2023 | Jun 30, 2023 | $204.00M | Feb 8, 2024 |
| FY2023 | Mar 31, 2023 | $217.00M | Feb 8, 2024 |
| FY2023 | Dec 31, 2022 | $254.00M | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | $275.00M | Feb 8, 2024 |
| FY2023 | Jun 30, 2022 | $215.00M | Feb 8, 2024 |
| FY2023 | Mar 31, 2022 | $200.00M | Feb 8, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $536.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $546.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.16B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.01B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $914.00M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $618.00M | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | $478.00M | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $276.00M | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $285.00M | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $264.00M | Feb 13, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $710.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $736.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $717.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $701.00M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $586.00M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $476.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $413.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $440.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $408.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $343.20M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.35B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.32B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.29B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $1.09B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $951.00M | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | $205.00M | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $230.00M | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $212.00M | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $226.00M | Feb 13, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.57B | Feb 9, 2023 |
| FY2022 | Dec 31, 2021 | $1.31B | Feb 9, 2023 |
| FY2022 | Dec 31, 2020 | $1.18B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $1.01B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.13B | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $1.18B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.04B | Feb 19, 2019 |
| FY2017 | Dec 31, 2015 | $867.90M | Sep 28, 2018 |
| FY2016 | Dec 31, 2014 | $801.80M | Feb 9, 2017 |
| FY2015 | Dec 31, 2013 | $718.80M | Feb 11, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.77B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $13.99B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $14.45B | Feb 11, 2026 |
| FY2023 | Dec 31, 2022 | $16.99B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $16.58B | Feb 9, 2023 |
| FY2022 | Dec 31, 2020 | $16.03B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $9.70B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $10.10B | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $9.79B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $8.83B | Feb 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.16B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $8.29B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $8.39B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $9.49B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $9.31B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $9.31B | Feb 15, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.44B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $5.53B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $5.83B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $7.22B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $6.95B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $6.43B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $4.71B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $4.23B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.72B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $3.22B | Sep 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.06B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.36B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $3.01B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $2.98B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $2.85B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $2.63B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $1.84B | Feb 15, 2022 |
| FY2019 | Dec 31, 2018 | $1.85B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.88B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $1.70B | Sep 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.57B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $6.41B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $6.15B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $7.45B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $6.67B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $6.30B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $5.94B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $5.34B | Feb 13, 2020 |
| FY2018 | Jan 1, 2018 | $4.53B | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $4.53B | Feb 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.84B | Feb 15, 2022 |
| FY2021 | Dec 31, 2020 | $1.65B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $832.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $739.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $545.30M | Feb 19, 2019 |
| FY2018 | Dec 31, 2016 | $443.70M | Feb 19, 2019 |
| FY2018 | Dec 31, 2015 | $577.70M | Feb 19, 2019 |
| FY2017 | Dec 31, 2014 | $797.80M | Sep 28, 2018 |
| FY2016 | Dec 31, 2013 | $939.50M | Feb 9, 2017 |
| FY2015 | Dec 31, 2012 | $715.70M | Feb 11, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $1.93B | Feb 13, 2020 |
| FY2019 | Dec 31, 2018 | $2.08B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.12B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $2.06B | Sep 28, 2018 |
| FY2016 | Dec 31, 2015 | $2.27B | Feb 9, 2017 |
| FY2015 | Dec 31, 2014 | $738.80M | Feb 11, 2016 |
| FY2014 | Dec 31, 2013 | $1.03B | Feb 12, 2015 |
| FY2013 | Dec 31, 2012 | $828.10M | Feb 13, 2014 |
| FY2012 | Dec 31, 2011 | $1.13B | Feb 14, 2013 |
| FY2011 | Dec 31, 2010 | $1.06B | Feb 14, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 13, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 13, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 207.06M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 218.67M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | 229.78M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | 234.12M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | 239.78M | Feb 9, 2023 |
| FY2020 | Dec 31, 2020 | 238.93M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | 206.41M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | 208.21M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | 210.81M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | 212.26M | Sep 28, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $98.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $130.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $161.00M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $162.00M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $146.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $140.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $142.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $124.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $113.40M | Feb 19, 2019 |